<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433120</url>
  </required_header>
  <id_info>
    <org_study_id>B-244 LuCamp</org_study_id>
    <nct_id>NCT01433120</nct_id>
  </id_info>
  <brief_title>Targeting the Gut Microbiome to Investigate the Pathways of Progression From Obesity to Metabolic Diseases in an At-risk Population.</brief_title>
  <official_title>Targeting the Gut Microbiome to Investigate the Pathways of Progression From Obesity to Metabolic Diseases in an At-risk Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lundbeck Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies of the human gut microbiome have suggested that treatment or prevention aimed at the
      obese microbiome could influence the development of obesity-associated metabolic
      disturbances.

      The objective of this project is to explore if a dietary intervention in 60 obese women with
      the probiotic Lactobacillus paracasei ssp paracasei F19 or flax seed fibres targeting the gut
      microbiome, can reduce insulin resistance, low-grade inflammation or dyslipidaemia, and to
      explore the interaction between the human genome and the gut microbiome.

      The study is based on the following hypotheses:

        -  Treatment with the probiotic Lactobacillus paracasei ssp paracasei F19 and flax seed
           fibres will lower the metabolic risk profile in the intervention groups compared with
           placebo.

        -  The effect on the metabolic risk markers can be correlated with changes in the gut
           microbiota (measured in faeces).

      After completion of the dietary intervention, the participants are offered a 10-week weight
      reduction program. Those who participate in the weight-loss program are invited to an
      optional follow-up visit in connection with the last visit at the clinical dietician, for the
      purpose of exploring the effect of weight loss on the gut microbiota and obesity-associated
      metabolic disturbances.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Week 0,6</time_frame>
    <description>3H OGTT (75g glucose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the gut microbiota</measure>
    <time_frame>Week 0,6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Week 0,4,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>Week 0,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fat mass and abdominal fat</measure>
    <time_frame>Week 0,6</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Probiotic L. casei F19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Flax seed fibres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus paracasei ssp paracasei F19</intervention_name>
    <description>10^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)</description>
    <arm_group_label>Probiotic L. casei F19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flax seed fibres</intervention_name>
    <description>10 grams of flax seed fibres per day (baked into two breakfast buns)</description>
    <arm_group_label>Flax seed fibres</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin (Placebo)</intervention_name>
    <description>Maltodextrin is dissolved in a glas of water once per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal

          -  BMI between 30-45 kg/m2

          -  Waist circumference &gt; 80 cm

          -  High leukocyte count

        Exclusion Criteria:

          -  Medically-treated Type 2 diabetes or dyslipidaemia

          -  Use of antibiotics during the last 3 months

          -  Use of pro- or prebiotic supplements during the last 6 weeks

          -  Illnesses related to the gastro-intestinal tract

          -  History of psychiatric diseases (incl. depression)

          -  Liver disease

          -  Alcohol abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arne Astrup, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Human Nutrition, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen</name>
      <address>
        <city>Frederiksberg C</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.lucamp.org</url>
  </link>
  <link>
    <url>http://www.ihe.life.ku.dk</url>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Arne Astrup</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Prebiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

